Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

Funding for this conference was made possible in part by 1R13AI136762-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. Government.

The conference was supported by Gilead, which provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 15 of 15 from HIV Research for Prevention 2014
Plenary 03: Importance of Mucosa in Prevention Research
Utilizing NHP Models to Understand Mucosal HIV Transmission and Dissemination
Jake Estes
Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States
Genital Inflammation and HIV Risk in Prevention Research
Jo-Ann Passmore
University of Cape Town, Cape Town, South Africa
Mucosal Immune Assays in HIV Vaccine Clinical Trials
Omu Anzala
KAVI - Institute of Clinical Research (KAVI-ICR), University of Nairobi, Nairobi, Kenya
from HIV Research for Prevention 2014 on 30 October 2014 08:30-10:00
Oral Abstract Session 21: Viral Transmission Studies
Transmission of Pre-adapted Viruses Determines the Rate of CD4 Decline in Seroconverters from Zambia
Daniela Monaco
Emory University, Atlanta, GA, United States
The Sequence of the α4β7-binding Motif on Gp120 of Transmitted/Founder Viruses Contributes to the Dependence on the Integrin for HIV Infection
Simone Richardson
Centre for HIV and STI's, National Institute for Communicable Diseases, Johannesburg, South Africa
HIV Replicative Capacity of Transmitted Viruses Is Associated with Early Immune Activation, Exhaustion and Establishment of the Viral Reservoir
Jessica Prince
Emory University, Atlanta, GA, United States
In-vitro Fitness of HIV-1 Transmitted/Founder versus Non-transmitted Full-length Genome Infectious Molecular Clones
Martin Deymier
Emory University, Atlanta, GA, United States
Genetic Footprints within the HIV-1 Envelope Glycoprotein Associated with Transmission in Men who Have Sex with Men
Damien Tully
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection
Gustavo Kijak
U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, Silver Spring, MD, United States
from HIV Research for Prevention 2014 on 30 October 2014 11:00-12:30
Oral Abstract Session 22: Cell and Tissue Models of ARVs for Prevention
Oral Maraviroc and Tenofovir for HIV Prevention in Women: An Ex vivo and Translational Approach
Melanie Nicol
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Pharmacodynamic Activity in Ectocervical and Colonic Tissue of Dapivirine, Maraviroc, and Combination Topical Gels for HIV Prevention
Charlene Dezzutti
University of Pittsburgh, Pittsburgh, PA, United States
Expression, Activity, and Regulation of Phosphorylating Enzymes in Genital and Colorectal Tissues and Immune Cells
Minlu Hu
Magee-Womens Research Institute, Pittsburgh, PA, United States
Transport and Transport Properties of Tenofovir from Microbicide Gels into Vaginal Tissue: Analysis Using Raman Spectroscopy
Oranat Chuchuen
Duke University, Durham, NC, United States
Mucosal Tissue Explants as Surrogates for in vivo Efficacy of Microbicides
Carolina Herrera
Imperial College, London, United Kingdom
Predicting Effective Truvada® PrEP Dosing Strategies With a Novel PK-PD Model Incorporating Tissue Active Metabolites and Endogenous Nucleotides (EN)
Mackenzie Cottrell
University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, United States
from HIV Research for Prevention 2014 on 30 October 2014 11:00-12:30
Oral Abstract Session 23: Pregnancy Intentions, Safe Conception and PMTCT
PrEP for Women: Indications and Worldwide Implementation for Women
Erika Aaron
Drexel Unviersity College of Medicine, Phila, PA, United States
Evaluation of HIV-1 Neutralizing Antibodies in Maternal-infant Transmission in Thailand
Brittani Barrows
Military HIV Research Program, Bethesda, MD, United States
PMTCT Adherence in Pregnant South African Women: The Role of Depression, Social Support, Stigma and Structural Barriers to Care
Nzwakie Mosery
MatCH Research (Maternal, Adolescent and Child Health Research), Durban, South Africa
Barriers and Promoters to Uptake of Safer Conception Strategies among HIV-serodiscordant Couples with Fertility Intention in Mbarara, Uganda
Lynn Matthews
MGH Center for Global Health & Division of Infectious Disease, Boston, MA, United States
"I Would Say it Does Concern Me and on the Other Hand it Doesn't." Perceptions of South African Learners' Experiences with Sex, Pregnancy, and HIV
Cecilia Milford
MatCH Research, Durban, South Africa
from HIV Research for Prevention 2014 on 30 October 2014 11:00-12:30
Oral Abstract Session 24: Mucosal Responses
Vaccine Induced Responses in a SIV Model Can Impact Challenge Outcomes
Megan Wise
University of Pennsylvania, Philadelphia, PA, United States
Local HIV-specific IgA Antibody Production in the Penile Urethra Mucosal Compartment
Kadryn Kadasia
Boston University, Boston, MA, United States
Targeting Mucosal Fc-Fc Receptor Interactions as Vaccine Strategy against Mucosal HIV-transmission
Magdalena Sips
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
DNA and Protein Co-immunization Improves the Magnitude, Longevity, and mucosal Dissemination of Immune Responses
George Pavlakis
National Cancer Institute at Frederick, Frederick, MD, United States
Antibody Isotypes Differ in their Capacity to Bind, Capture and Aggregate HIV-1 Virions
Sandra Okala
Imperial College London, London, United Kingdom
Transcriptional Signatures of Viral Control in HIV-1 Infected South African Women
Nikki Gentle
University of the Witwatersrand, Johannesburg, South Africa
from HIV Research for Prevention 2014 on 30 October 2014 11:00-12:30
Oral Abstract Session 25: Adjuvants and Immunogens
Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition
Genoveffa Franchini
National Cancer Institute, Bethesda, MD, United States
IgG Glycosylation Is Programmed and Remembered after Immunization with TLR Stimulating Adjuvants
Alison Mahan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
CD4-induced Epitopes Are Exposed on Cell-bound HIV-1: The Key to Fc Receptor Mediated Humoral Immunity?
Meron Mengistu
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States
Structural Evolution of HIV-1 gp120 Glycan Recognition by the PGT121 Lineage of Potent Broadly Neutralizing Antibodies
Fernando Garces
Dept of Integrative Structural & Computational Biol, The Scripps Research Institute, IAVI Neutralizing Antibody Center, Scripps CHAVI-ID, La Jolla, CA, United States
Refocussing Antibody Responses by Chemical Modification of Vaccine Antigens
Torben Schiffner
University of Oxford, Oxford, United Kingdom
Native-like BG505 SOSIP.664 Trimers Induce Autologous Tier-2 NAbs against Complex Epitopes in Rabbits and Macaques
John Moore
Weill Medical College, New York, NY, United States
from HIV Research for Prevention 2014 on 30 October 2014 11:00-12:30
Oral Abstract Session 26: Microbicides and Multipurpose Prevention Technologies
Introduction of the SILCS Diaphragm as a Multipurpose Technology in South Africa: Potential Users, Perceived Benefits, and Barriers to Use
Cecilia Milford
MatCH Research, Durban, South Africa
Development of Reservoir Vaginal Rings Containing Dapivirine or Hormonal Contraceptive Steroids
Susan Fetherston
University of Ulster, Coleraine, United Kingdom
Engineering a "Virus Trap and Safety Net" Microbicide
Jill Steinbach
University of Louisville, Louisville, KY, United States
A Single Dose Novel Formulation of Maraviroc Using Electrospun Fabrics Designed for Instant and Multi-day HIV Prevention
Cameron Ball
University of Washington, Seattle, WA, United States
Mass Spectrometry Imaging of Hair Strands Allows for Evaluation of Long Term Antiretroviral Adherence
Corbin Thompson
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
from HIV Research for Prevention 2014 on 30 October 2014 13:30-15:00
Oral Abstract Session 27: PrEP: Self-testing, Safety and Modeling
Selection of Rilpivirine Resistant HIV-1 in a Seroconverter on Long-acting Rilpivirine (TMC278LA) from the Lowest Dose Arm of the SSAT 040 Trial
Kerri Penrose
University of Pittsburgh, Pittsburgh, PA, United States
Uptake of HIV Self-testing among People Receiving PrEP in Kenya
Kenneth Ngure
Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya
The Better it Is, the More it Will Be Used - The Synergistic Relationship between Product Efficacy, Level of Uptake and Overall Impact
Fern Terris-Prestholt
London School of Hygiene and Tropical Medicine, London, United Kingdom
The Potential Impact of Long-acting PrEP on HIV Transmission, Mortality and Drug Resistance in KwaZulu-Natal, South Africa: Model-based Analyses
Ume Abbas
Cleveland Clinic, Cleveland, OH, United States
A Phase 1 Open Label Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Intramuscular TMC278 LA (the MWRI-01 Study)
Ian McGowan
University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
from HIV Research for Prevention 2014 on 30 October 2014 13:30-15:00
Oral Abstract Session 28: Treating and Preventing: the Role of ARVs
High Initiation and Adherence among High Risk African HIV Discordant Couples in a Demonstration Project of PrEP and ART for HIV Prevention
Renee Heffron
University of Washington, Seattle, WA, United States
Evaluation of a Risk Score Tool to Identify Higher-risk HIV-1 Serodiscordant Couples for Antiretroviral-based HIV-1 Prevention
Nelly Mugo
Kenya Medical Research Institute (KEMRI), Kenya
Facing the Realities of HIV Universal Test and Treat: Early Lessons Learnt from the Delivery of the HPTN071/ PopART Study Intervention in Zambia
Kwame Shanaube
ZAMBART Project, Lusaka, Zambia
HIV Transmission in Discordant Couples in Non Research Settings: Rwanda Experience
Susan Allen
Emory University, Atlanta, GA, United States
Mathematical Modelling to Estimate the Impact and Cost-effectiveness of TasP, PrEP and Condom Promotion for Serodiscordant Couples in Nigeria
Fern Terris-Prestholt
London School of Hygiene and Tropical Medicine, London, United Kingdom
from HIV Research for Prevention 2014 on 30 October 2014 13:30-15:00
Oral Abstract Session 29: T Cell Immunity
Dendritic Cells from HIV-1 Neutralizers Efficiently Induce the Generation of CXCR5+ CXCR3+ PD1Lo CD4 T Cells with B Cell Helper Function
Enrique Martin-Gayo
Ragon Institute of MIT, MGH and Harvard, Boston, MA, United States
Massive Activation, Expansion and Subsequent Apoptosis of CD8 T-cells in Acute HIV Infection
Zaza Ndhlovu
University of KwaZulu-Natal, Durban, South Africa
Reduction in Breadth and Not Polyfunctionality or Proliferative Capacity of CD8+ T Cells Is Associated with Loss of Virologic HIV Control
Catherine Koofhethile
University of KwaZulu Natal, Durban, South Africa
Paradigm-violating HLA Class II-restricted CD8 T-cells in HIV-infection
Srinika Ranasinghe
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
Anti-viral CD8 T-cells with B-cell Follicle Homing Potential Contribute to Vaccine-mediated Enhanced Control of Pathogenic SIV Infection
Rama Amara
Emory University, Atlanta, GA, United States
A Novel T-cell Vaccine Eliciting T-cell Specificities Associated with Control of HIV-1 In Humans Is Highly Immunogenic in Mice and Macaques
Beatriz Mothe
IrsiCaixa AIDS Research Institute-HIVACAT, Badalona, Spain
from HIV Research for Prevention 2014 on 30 October 2014 13:30-15:00
Oral Abstract Session 30: Antibody Functions and Protection
Synthetic Nucleic Acid Antibody Prophylaxis with Electroporation Drives Biologically Relevant Anti-HIV-1 Envelope Responses in vivo
Niranjan Sardesai
Inovio Pharmaceuticals, Inc., Blue Bell, PA, United States
Insights on Synergistic Antibody-dependent Cellular Cytotoxicity (ADCC) Activity Mediated by Mutant Human Monoclonal Antibodies against HIV-1 Env
Chiara Orlandi
University of Maryland, Baltimore, MD, United States
The Impact of Antiretroviral Treatment on HIV-1-Specific Broadly Neutralizing Antibody Responses
Nonhlanhla Mkhize
National Institute for Communicable Diseases of the NHLS, Johannesburg, South Africa
Topical Application of Broadly Neutralizing Monoclonal Antibodies Reduces HIV Infection of Mucosal Tissue
Yanille Scott
University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, United States
Isolation of Monoclonal Antibodies from a SHIV-AD8 Infected Rhesus Macaque with Broad Neutralizing Activity
Rebecca Lynch
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
Heterogeneous Conformation of HIV-1 Envelopes on Individual Virions
Leonid Margolis
NIH/NICHD, Bethesda, MD, United States
from HIV Research for Prevention 2014 on 30 October 2014 13:30-15:00
Round Table 03: Diffusion of Innovation: Accelerating Along the Research to Rollout Continuum
HIV Prevention: Moving from Evidence to Demonstration Projects to Policy and Programs
Connie Celum
University of Washington, Seattle, WA, United States
Rapid rapid-scale-up of VMMC
Dirk Taljaard
CHAPS, Johannesburg, South Africa
Challenges for Prep Implementation in the US
Keith Rawlings
Gilead Sciences, Foster City, CA, United States
From Research Result to Public Health Impact: What Have we Learned and how Can we Do it Better and Faster
Mitchell Warren
AVAC, New York, NY, United States
Round Table Discussion: Diffusion of Innovation: Accelerating Along the Research to Rollout Continuum
Connie Celum
University of Washington, Seattle, WA, United States
Dirk Taljaard
CHAPS, Johannesburg, South Africa
Keith Rawlings
Gilead Sciences, Foster City, CA, United States
Mitchell Warren
AVAC, New York, NY, United States
from HIV Research for Prevention 2014 on 30 October 2014 15:30-17:00
Round Table 04: Research Where and With Whom it Matters
MSM: Long Road to Trial Participation in Africa
Eduard Sanders
KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
We are not Guinea Pigs: HIV Clinical Research for Smarties
Udom Likhitwonnawut
AVAC, Chiang Mai, Thailand
Fareed Abdullah
The South African National AIDS Council, South Africa
Engaging Adolescents and Young Adults in HIV Prevention Trials
Sybil Hosek
Stroger Hospital of Cook County, Chicago, IL, United States
African Couples Testing Matters: Most Transmissions Are in Marriage, Most Pregnancies Are Not Immaculate Conceptions, and Women Aren´t Just Incubators
Susan Allen
Rwanda Zambia HIV Research Group-Emory University, Atlanta, GA, United States
Round Table Discussion: Research Where and With Whom it Matters
Eduard Sanders
KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Udom Likhitwonnawut
AVAC, Chiang Mai, Thailand
Fareed Abdullah
The South African National AIDS Council, South Africa
Sybil Hosek
Stroger Hospital of Cook County, Chicago, IL, United States
Susan Allen
Rwanda Zambia HIV Research Group-Emory University, Atlanta, GA, United States
from HIV Research for Prevention 2014 on 30 October 2014 15:30-17:00
Symposium 08: Mucosal Barriers to Infection
Upper Female Genital Tract and Defining Safety
Ruth Greenblatt
University of California San Francisco, San Francisco, CA, United States
Behavioral and Biological Factors Affecting HIV Acquisition in Women
Douglas Kwon
Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, United States
Mechanisms of HIV-1 Restriction and Dissemination Mediated by Intestinal Mucosal Myeloid Cells
Gabriella Scarlatti
San Raffaele Scientific Institute, Milan, Italy
Rectal Microbicide Development: An Update
Ross Cranston
University of Pittsburgh, Pittsburgh, PA, United States
from HIV Research for Prevention 2014 on 30 October 2014 15:30-17:00
Symposium 09: Sustaining Durability of Responses
Clinical Translation of HIV Protein-Expressing Cytomegalovirus Vectors
Louis Picker
Oregon Health & Science University, Beaverton, OR, United States
Antibody Persistence and T Cell Balance: Two Key Factors Confronting HIV Vaccine Development
George Lewis
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States
Adjuvants and Durability of Vaccine-Induced Immunity
Marguerite Koutsoukos
GlaxoSmithKline, Rixensart, Belgium
Integrase Defective Lentiviral Vectors for Induction of Persistent and Functional Immune Responses
Andrea Cara
Istituto Superiore di Sanità, Rome, Italy
from HIV Research for Prevention 2014 on 30 October 2014 15:30-17:00
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 15 of 15 from HIV Research for Prevention 2014